The Patent Finder

Allegro Pharmaceuticals, LLC

9 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Nov 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 4 to 13, 2026 · next Dec 4
  • 1 fee due Sep 17, 2027
    The maintenance fee for Peptides useable for treating cancer (US 10,590,166) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
  • 1 fee due Nov 5, 2027
    The maintenance fee for Peptides useable for treatment of disorders of the eye (US 10,639,347) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 9,872,886Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,307,460Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,590,166Peptides useable for treating cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,639,347Peptides useable for treatment of disorders of the eye
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,666,625Pharmaceutical compositions and preparations for administration to the eye
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,896,480Integrin receptor antagonists and their methods of use
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,673,914Peptide therapies for reduction of macular thickening
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,018,352Peptide Compositions
In force
 · High confidence
In forceHigh confidence
US 12,454,549Treatments for diseases and disorders that involve oxidative stress
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 9: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited